Testing BG-75202 for blood cancers that came back
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new drug called BG-75202, alone or combined with other treatments, for myeloid malignancies (blood cancers affecting bone marrow cells) that have returned or stopped responding to previous treatment. The goal is to see if this drug can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been diagnosed with a myeloid malignancy (a blood cancer) that came back or stopped responding after at least one prior treatment
- If your cancer has a known genetic mutation that can be targeted, you must have already received the matching targeted therapy (unless it was not available, not safe for you, or you chose not to take it)
- You are in reasonably good health, able to care for yourself with minimal assistance (ECOG score 0–2)
- You have never received a KAT6A or KAT6B inhibitor or degrader before
- Your cancer has not spread to your brain or central nervous system
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug called GLB-001 for people with certain blood cancers or bone marrow disorders that have not gotten better with standard treatments. The goal is to see if the drug is safe and how well it works.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
This trial tests a new drug called BT02 for people with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or stopped responding to treatment. The goal is to see if BT02 can help when other treatments haven't worked.
This trial tests a new treatment, BG1805, for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It targets a specific marker on leukemia cells called CLL-1.
This study tests a new drug called HRS-3005 in patients with B-cell blood cancers that have come back or stopped responding to prior treatment. The trial aims to find the right dose and understand how well the drug works and what side effects it causes.
Hear when a new Myeloid Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.